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ABSTRACT  
Post-translational modifications (PTMs) of sarcomeric proteins could participate to left 
ventricular (LV) remodeling and contractile dysfunction leading in advanced heart failure (HF) 
with altered ejection fraction. Using an experimental rat model of HF (ligation of left coronary 
artery) and phosphoproteomic analysis, we identified an increase of desmin phosphorylation and 
a decrease of desmin O-N-acetylglucosaminylation (O-GlcNAcylation). We aim to characterize 
interplay between phosphorylation and O-GlcNAcylation for desmin in primary cultures of 
cardiomyocyte by specific O-GlcNAcase (OGA) inhibition with thiamet G and silencing O-
GlcNAc transferase (OGT) and, in perfused heart perfused with thiamet G in sham- and HF-rats. 
In each model, we found an efficiency of O-GlcNAcylation modulation characterized by the 
levels of O-GlcNAcylated proteins and OGT expression (for silencing experiments in cells). In 
perfused heart, we found an improvement of cardiac function under OGA inhibition. But none of 
the treatments either in in vitro or ex vivo cardiac models, induced  a modulation of desmin, 
phosphorylated and O-GlcNAcylated desmin expression, despite the presence of O-GlcNAc 
moities in cardiac desmin. Our data suggests no interplay between phosphorylation and O-
GlcNAcylation of desmin in HF post myocardial infarction. The future requires finding the 
targets in heart involved in cardiac improvement under thiamet G treatment. 
 
1 INTRODUCTION 
Heart failure (HF) following myocardial infarction (MI) is characterized by alterations of left 
ventricle (LV) structure and function, known as LV remodeling (1); this pathophysiological 
process is a strong predictor of both HF and death as we recently showed in two cohorts of 
patients REVE and REVE2  dedicated to the analysis of LV remodeling (2,3).  The long-term (> 
10 years) clinical follow-up of patients included in these two cohorts has shown that LV 
remodeling remains independently associated with HF and cardiovascular death (4). 
Evaluation of post-translational modifications (PTM) of sarcomeric cardiac proteins is a 
promising new approach to studying the mechanisms of HF. The phosphorylation status of 
sarcomeric proteins is altered in HF and may thus contribute to the decreased cardiac function 
(5). Another rapid, dynamic, and reversible PTM is O-N-acetylglucosaminylation (O-
GlcNAcylation) (6). Both phosphorylation and O-GlcNAcylation regulate numerous cellular 
functions by reversibly adding either phosphate or O-N-acetylglucosamine (O-GlcNAc) to 
proteins. The crosstalk between these two PTMs may occur by steric competition for occupancy 
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at the either the same or a proximal amino acid site (7). Specific sites of O-GlcNAcylation 
described in some cardiac myofilament proteins have suggested that O-GlcNAc and O-phosphate 
modifications of these proteins may interact dynamically (8,9). 
Recently, we have demonstrated interplay between Ser
208
-phosphorylation and Ser
190
-O-
GlcNAcylation of troponin T in ischaemic HF, linked to decreased activity of both PKCε and O-
GlcNAcase (OGA) and increased O-GlcNAc transferase (OGT) activity (10). We also showed 
recently than another sarcomeric protein, desmin has been identified by differential proteomic 
analysis to have increased levels of phosphorylation in LV of HF-rats compared to the sham-rats 
(11). In addition, we found a 2-fold increased serine-desmin phosphorylation in the LV of HF-
rats, mainly in the insoluble fraction, suggesting the formation of desmin aggregates, toxic for the 
cardiomyocyte. Desmin is a 53 kDa protein, particularly localized to the Z-band and is 
considered as a major integrator of contractile apparatus and a critical factor for maintaining 
intermediate filament structure. Its increased phosphorylation might lead to the network 
destabilization and formation of aggregates toxic for the cardiomyocyte (12). 
Our objectives were to characterize 1) whether the levels of O-GlcNAcylated desmin are 
regulated in cardiomyocyte by inhibition or activation of O-GlcNAcylation in in vitro and ex 
vivo cardiac models of HF and; 2) whether modulation of O-GlcNAcylation impacts the 
phosphorylation levels of desmin with the aim to decrease the phosphorylation levels of desmin 
and the formation of desmin aggregates following HF development. 
2 MATERIALS AND METHODS 
2.1 Experimental rat model of ischemic heart failure 
All animal experiments were performed according to the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health (NIH publication NO1-
OD-4-2-139, revised in 2011). Animals were used and experimental protocols performed under 
the supervision of a person authorized to perform experiments on live animals (F. Pinet: 59-
350126). Approval was granted by the institutional ethics review board (CEEA Nord Pas-de-
Calais N°242011, January 2012). Before surgery, rats were anaesthetized (sodium methohexital, 
50 mg/kg intraperitoneal (IP)), while analgesia was administered before (xylazine 5 mg/kg IP) 
and 1 hr after surgery (xylazine 50 mg/kg subcutaneously) as previously described (13). MI was 
induced in 10-week-old male Wistar rats (Janvier, Le Genest St isle, France) by ligation of the 
left anterior descending coronary artery according to the method previously described (1,13). 
Haemodynamic and echocardiographic measurements were taken at 2 months after surgery, 
followed by heart excision as previously described (14). Tissues were kept at -80°C until 
analysis. 
2.2 Isolated heart perfusion 
In vitro LV function was determined in randomly selected control male Wistar rats either 
untreated (bodyweight: 453 ± 7 g) or treated (bodyweight: 444 ± 14 g) with 100 µL OGA 
inhibitor, Thiamet G (200 µM diluted in saline buffer, Sigma-Aldrich, Lyon, France) for 2 hours. 
After anaesthesia (50 mg/kg of sodium pentobarbital injected intraperitoneally), the heart was 
rapidly excised and plunged in ice-cold oxygenated KH buffer (5.5 mM glucose, 1.25 mMCaCl2, 
120 mM NaCl, 31 mM NaHCO3, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, [pH 7.4]) as 
previously described (10). The heart was transferred within 30 seconds to a Langendorf heart 
perfusion apparatus and perfused at constant hydrostatic pressure (90 mm Hg). A balloon was 
inserted into the LV and connected to a pressure transducer to record LV (systolic and diastolic) 
pressure, LV developed pressure and heart rate for 25 minutes. The balloon was inflated with 
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water, allowing a similar and constant LV distending pressure of 10 mm Hg. At the end of each 
experiment, the LV was snap-frozen in liquid nitrogen and stored at -80°C until analysis. 
2.3 Cell Culture 
2.3.1 Primary cultures of neonatal rat cardiomyocytes  
Primary cultures of rat neonatal contractile cardiac myocytes (NCM) were prepared from heart 
ventricles of 1- or 2-day-old rats as previously described (10). Briefly, cardiac cells of newborn 
rats’ ventricles were dissociated by enzymatic digestion with 0.04% collagenase II (Worthington, 
Lakewood, NJ, USA) and 0.05% pancreatin (Sigma-Aldrich). Non-NCM were removed by 30 
min centrifugation at 1,600 g in a discontinuous Percoll gradient (bottom 58.5%, top 40.5% [v/v], 
Sigma-Aldrich). NCM were then seeded at a density of 4×10
5
 cells per well in 6-well plates 
coated with 0.01% of collagen (Sigma-Aldrich) (8×10
5
 cells per well when they are seeded on 
coverslip) and cultured in a medium containing DMEM/Medium199 (4:1), 10% horse serum 
(Life Technologies), 5% fetal bovine serum (FBS) (ATCC), 1% penicillin and streptomycin 
(10,000 U/mL, Life Technologies) for 7 days at 37°C under 5% CO2 atmosphere. 
2.3.2 Small interfering RNA transfection 
The first two individual pre-designed specific siRNA specifically targeting rat OGT mRNA, 
rat OGT and non-targeting control were used (ON-TARGETplus siRNA, Dharmacon, GE 
Healthcare). NCMs were plated (100,000 cells/well) in 6-well plates and were allowed to grow 
for 24h without antibiotics. The first 2 individual OGT (OGT1 and OGT2) siRNAs (5 nmol/L) 
were transfected with the DharmaFECT® reagent (4 µL) according to the manufacturer’s 
recommendations. Total cell extracts were collected 72 h after transfection. 
2.4 Protein extraction 
Proteins from human hearts and rat LVs were extracted from frozen tissues (after removing 
the infarcted area) with Dounce-Potter homogenization into ice-cold RIPA buffer (50 mM Tris 
[pH7.4], 150 mM NaCl, 1% Igepal CA-630, 50 mM deoxycholate, and 0.1% SDS) containing 
antiproteases (Complete
TM
 EDTA-free, Roche Diagnostics), serine/threonine and tyrosine protein 
phosphatase inhibitors (Phosphatase inhibitor Cocktail 2 and 3, Sigma-Aldrich), 1 mM Na3VO4 
and PUGNAC (50 µM). After 1 hr incubation at 4°C, the homogenate was centrifuged at 15,300 
g for 15 min at 4°C and the supernatant containing soluble proteins was collected. After 
treatments, cells were rinsed twice with PBS before being mechanically scraped from the plate in 
50 µL of ice-cold RIPA buffer. Soluble and insoluble proteins were extracted as describe above. 
Protein concentrations for all samples were determined with a Bradford-based method protein 
assay (Biorad, Marnes-la-Coquette, France). 
2.5 Immunoprecipitation, Western blot, Phos-Tag
TM
 and WGA gels 
2.5.1 Immunoprecipitation 
Immunoprecipitation was performed with 50 µg of NCM proteins or 100 µg of LV proteins 
pre-cleared by incubation with protein A/G magnetic beads (88802, Pierce) for 1 hr at 4°C with 
gentle shaking. The pre-cleared proteins were then mixed with 2 µL of anti-desmin antibody 
(ab3236, Abcam) diluted in 100 µL of RIPA 1X buffer as previously described (11). After 
overnight incubation at 4°C on a rotating device, immune complexes were precipitated at 4°C for 
only 2 hrs on a rotating device with 35 µL of protein A/G magnetic beads. Immunoprecipitated 
(IP) complexes were then washed four times with 750 µL of RIPA 1X buffer before denaturation 
in Laemmli buffer at RT for western blot analysis. 
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2.5.2 Western blot  
Soluble proteins (10-50 μg) were analysed on 12% SDS-PAGE gels. Proteins were transferred 
to nitrocellulose membranes and blocked for 1 hr in Tris-buffered saline with 0.1% [v/v] Tween-
20 (TBS-T) containing 5% [w/v] skim milk or BSA with constant shaking. Membranes were then 
incubated with primary antibodies diluted in TBS-T with 5% skim milk or BSA overnight at 4°C 
with constant shaking. The blots were then washed with TBS-T and incubated at RT with 
horseradish peroxidase labelled secondary antibodies diluted in 5% skim milk or BSA/TBS-T for 
1 hr. Following the secondary incubation, the membranes were washed with TBS-T before blots 
imaging. Equal protein loading was confirmed using GAPDH and sarcomeric actin 
immunoblotting. 
For western blots of desmin-IP proteins, membranes were first incubated with RL2 antibody 
diluted in 5% fresh BSA overnight at 4°C before incubation with other antibodies. 
2.5.3 Phos-tag
TM
 gels 
Soluble proteins were analysed on 10% gels containing 40 µM of Phos-tag™ (Wako, Osaka, 
Japan) and 100 µM of Mn
2+
 at 90V for 2.5 hrs. The excess of metal was removed by washing the 
gels three times for 10 min in transfer buffer (NuPAGE® Transfer Buffer, Invitrogen) containing 
10% methanol and 10 mM EDTA and then three times for 10 min in transfer buffer containing 
10% methanol before the proteins were transferred onto 0.2 µm PVDF membrane. To detect 
desmin and its phosphorylated forms, membranes were blocked 1 hr in 5% skim milk/TBS-T 
before overnight incubation at 4°C with desmin antibody diluted 1/1000 in blocking solution. The 
following steps were similar to those described above for western blot. Briefly, the Phos-tag™ 
molecules incorporated into the SDS-PAGE are able with the cooperation of two Mn
2+
 metal 
cations to slow down the migration of phosphorylated proteins. Therefore, phosphorylated 
desmin migrates at higher apparent molecular weight than the non-phosphorylated form. 
However, at equivalent phosphorylation levels, the position of the phosphate group can also 
influence the apparent molecular weight of a protein in a Phos-tag™ gel. 
2.5.4 WGA 
Soluble proteins (50 µg) were analysed on 7% gels containing 3.75 mg/mL of  Wheat Germ 
Agglutinin (WGA) (L9640, Sigma-Aldrich) at 4°C at 20 mA for 2 hrs as previously described 
(15). After migration, the same protocol for protein transfer and incubation with primary and 
secondary antibodies as for classical western blot was applied. 
2.5.5 List of antibodies  
 
Protein Sample 
Reference 
Company 
Dilution antibodies 
 
Desmin 
 
Heart ab32362 
Abcam 
1/1000 
NCM 1/5000  
 
O-GlcNac Heart/NCM 
NB300-524 (RL2) 
Novus Biological 
1/2000 
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OGT NCM 
clone DM17, O6264 
Sigma-Aldrich 
1/1000 
GAPDH Heart/NCM 
sc-36562 
Santa Cruz 
1/5000 
  
Phospho-serine Heart/NCM P5747, Sigma-Aldrich 1/1000 
Sarcomeric actin Heart /NCM 
MO874 1/2000 
  Dako 
 
2.5.6 Blots imaging 
The Chemidoc® XRS+ camera (Biorad) and the Image Lab™ software were used for blots 
imaging and densitometry analysis. Membranes were incubated for 5 min with Clarity™ Western 
ECL Substrate (Biorad) before imaging. The signal was quantified from the image obtained just 
before saturation. The band corresponding to the protein of interest was framed within a defined 
area to express the signal intensity depending of the area. This value was related to the intensity 
value of the reference protein (GAPDH or sarcomeric actin). The values were expressed in 
arbitrary units (U.A.). 
2.6  Statistical Analysis 
Data expressed as means ± SEM were analyzed with GraphPad Prism version 6.01 (GraphPad 
Software, San Diego, CA) and comparisons were made by Student's t test, Mann-Whitney (two-
tailed), one- or two-way analysis of variance (ANOVA) with Tukey's post hoc test, as 
appropriate. Results were considered statistically significant if the p<0.05. 
3 RESULTS 
3.1 Post-translational modification of desmin heart failure rats 
Cardiac remodeling and dysfunction in HF-rats was characterized at 2 months post-MI by 
significant increases in LV end-diastolic pressure, LV end-diastolic and end-systolic diameters, 
and LV weight as previously shown (10). We previously investigated cardiac phosphoproteomic 
changes associated with LV remodeling and dysfunction in this HF-rat model. At 2 months after 
surgery, proteomic analysis revealed different LV phosphoproteomic patterns between the sham- 
and HF-rats (16). We previously identified two spots as being desmin (11). We highlighted a 
significant increase of desmin phospho-species in LV of rats 2 months after MI compared to 
controls (Fig. 1A) without any modulation of total desmin protein levels (Fig. 1B). Then, we 
looked for interplay between phosphorylation and O-GlcNAcylation of desmin in the same 
experimental model and found a significant decrease of O-GlcNAcylated desmin in LV of HF 
rats compared to controls (Fig. 1C). These data showed that desmin may bear O-GlcNAc residues 
and that the levels of O-GlcNAcylated desmin were inversely related to the levels of 
phosphorylated desmin in LV of HF rats. To confirm these data, we tested several modulators of 
O-GlcNAcylation in several in vitro and ex vivo models, such as primary culture of 
cardiomyocyte (NCM) and isolated perfused heart. 
 
3.2 Modulation of O-GlcNAcylation in vitro in primary cultures of neonate cardiomycytes 
3.2.1 Inhibition of OGA by thiamet G 
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First, we studied the impact of OGA inhibition by thiamet G in primary cultures of neonate rat 
cardiomyocytes (NCM) as designed (Fig. 2A) and observed a significant increase of O-
GlcNAcylated proteins (1.16 ± 0.09 vs. 2.55 ± 0.27, P <0.01) (Fig. 2B). Thiamet G treatment has 
no effect on total desmin levels (Fig. 2C) nor on desmin phosphospecies (Fig. 2D). To quantify 
the levels of O-GlcNAcylated desmin, we used immunoprecipitation (IP) of desmin species 
followed by a western blot with RL2 antibody to detect O-GlcNAcylated proteins (Fig. 2E). We 
verified by desmin western blot the efficiency of IP with desmin detected in input, IP (IP Des) 
and supernatant of IgG IP (S igG) but not in supernatant of desmin IP (S Des). The specificity of 
this approach was also verified with no O-GlcNAcylated proteins detected in beads. As observed 
the levels of O-GlcNAcylated desmin was very low in NCM and we did not observe any 
modulation in NCM treated with thiamet G (Fig. 2E) 
 
3.2.2 Silencing of OGT 
Second, we studied the impact of OGT silencing in primary cultures of neonate rat 
cardiomyocytes (NCM) as designed (Fig. 3A) and observed a significant decrease of O-
GlcNAcylated proteins (1.08 ± 0.03 vs. 0.54 ± 0.08 (OGT1) and 0.52 ± 0.07 (OGT2), P <0.05) 
that is due to the significant decrease of OGT validating the efficiency of OGT silencing (0.99  ± 
0.13 vs. 0.23 ± 0.02 (OGT1) and 0.20 ± 0.05 (OGT2), P <0.01) (Fig. 3B). Both OGT siRNA1 
and siRNA 2 did not show any effect on total desmin levels (Fig. 3C) nor in desmin 
phosphospecies (Fig. 3D). We then quantified the levels of O-GlcNAcylated desmin as described 
in Figure 2E. Conversely, we observed an unspecific low intensity band for O-GlcNAcylated 
desmin with beads but we did not observe any modulation of O-GlcNAcylated desmin after OGT 
silencing in NCM (Fig. 3E). 
 
3.3 Modulation of O-GlcNAcylation ex vivo in isolated perfused heart 
In isolated perfused hearts, we assessed the functional cardiac modification induced by 
thiamet G, a specific OGA inhibitor, injected 2 h before the perfusion (Fig. 4A). Thiamet G 
decreased significantly the coronary flow in only sham-rats. In HF-rats, thiamet G increased 
significantly LV developed pressure and cardiac output without any effect on heart rate (Table).  
We validated by western blot the inhibitory effect of OGA by thiamet G with significant 
increase of O-GlcNAcylated LV proteins in sham- and HF-rat heart perfused with the inhibitor 
(Fig. 4B). We found a significant decrease of total desmin expression in LV from HF-rat perfused 
compared to the sham-rats independently of thiamet G perfusion (Fig. 4C). We visualized desmin 
phosphospecies by desmin immunoblot of Phos-tag™ gels and we did not find any modulation 
with different molecular weight desmin species detected in thiamet G-perfused heart (Fig. 4D). 
 
3.4 New technology to detect O-GlcNAcylated proteins 
Due to the difficulties to detect specifically O-GlcNAcylated desmin in LV proteins either 
from cultures of cardiomyocytes or perfused heart, we compare the sensitivity of 2 methods, 
western blots of O-GlcNAcylated LV proteins separated with classical SDS-PAGE gel (Fig. 5A) 
and WGA-SDS-PAGE gel (Fig. 5B) as recently described (15). First, red ponceau staining of the 
transferred membranes showed a less sensitivity to detect protein profiles with WGA gel. But 
conversely, we observed for the detection of O-GlcNAcylated LV proteins with RL2 antibody a 
stronger signal of better quality with WGA gel (Fig. 5B) by comparison to SDS gel (Fig. 5A). 
We then tested the detection of desmin in WGA gel and only found one band with a stronger 
signal in thiamet G treated samples either in sham- or HF-rats (Fig. 5B) that we were unable to 
quantify due to the strong background. 
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4 DISCUSSION 
Post-translational modifications of sarcomeric proteins play an important role in HF-induced 
cardiac dysfunction (17,18).  We previously found a 2-fold increased phosphorylation of desmin 
levels by phosphoproteomic analysis (11) in a well characterized rat ischemic HF experimental 
model in which the induction of anterior MI leads to LV remodeling and to HF (19). Nine serine 
resides conserved between species were identified by mass spectrometry to be phosphorylated 
(11). In the present study, we found a decrease of O-GlcNAcylation levels of desmin and we 
hypothesize that a cross-talk between phosphorylation and O-GlcNAcylation of desmin may 
occur during HF development as we have recently shown for troponin T in in the same rodent 
model of HF (10). Here, our aim was to determine whether the levels of O-GlcNAcylated desmin 
are regulated in cardiomyocytes by inhibition or activation of O-GlcNAcylation and whether 
modulation of O-GlcNAcylation impacts the phosphorylation levels of desmin, in order to 
identify the serine residues that could be involved in the interplay. 
For that purpose, first, we have modulated the levels of O-GlcNAcylated proteins in primary 
culture of neonate rat cardiomyocytes by either acting on OGA inhibition by treatment of the 
cardiomyocytes with a specific OGA inhibitor, thiamet G (20) or by OGT silencing. We verified 
that both treatments were efficient in primary cultures of cardiomyocytes with significant 
increase of O-GlcNAcylated proteins after OGA inhibition and significant decrease of O-
GlcNAcylated proteins after OGT silencing. With both treatments, we did not observe any 
changes in total desmin protein levels and in the expression of desmin PTMs: phosphorylation 
and O-GlcNAcylation.  
Second, we used an ex vivo model of perfused rat heart in order to test the efficiency of 
thiamet G on cardiac contractility. We found a positive impact of OGA inhibition on several 
cardiac parameters which were different depending on the sham- (coronary flow) or HF- (LV 
developed pressure and cardiac output) animals, except for the heart rate which was not modified 
in both groups of animals after a 2 hours perfusion of thiamet G. We verified the efficiency of 
OGA inhibition by the significant increase of O-GlcNAcylated proteins in perfused heart in both 
group of animals treated (1.4 fold, P<0.05). And as shown in in vitro experiments, we did not 
observe any modulation of total desmin and its phosphorylated forms, except a significant 
decrease of desmin expression between sham- and HF- rats after the 2 hours perfusion, that can 
be explained by a degradation during the perfusion, such as calpain (11). We found these 
negative results by 2 techniques: IP desmin followed by phospho-serine WB (not shown) and 
Phos-tag™ gels. 
Despite these negative results with in vitro and ex vivo cardiac models of O-GlcNAcylation 
modulation, we did not want to exclude that the technology used to quantify the levels of O-
GlcNAcylated desmin was inappropriate or not enough sensitive. To clarify this hypothesis, we 
have tested a technique recently published (15). Despite the less sensitivity of the technique to 
detect the proteins transferred into the membrane (red ponceau staining), we improved the quality 
of the profile of O-GlcNAcylated proteins by comparison to a classical western blot with the use 
of the same antibody against the O-GlcNAc moieties. Unfortunately, the quality of the WGA-
desmin blot did not allow quantifying the desmin band detected despite the highest intensity of 
desmin in thiamet G-treated LV samples. Further improvement will be required to use this 
promising technique to quantify the levels of O-GlcNAcylation of a specific protein. 
Our data have shown that despite the presence of O-GlcNAc moieties on desmin from heart, 
there is no regulation of O-GlcNAcylated desmin by modulators of O-GlcNAcylation and 
subsequently there is no interplay between phosphorylation and O-GlcNAcylation of desmin.  
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The future is to find the targets of O-GlcNAcylation in heart that can be involved in cardiac 
improvement and to find the pharmacological agents able to decrease the levels of 
phosphorylated desmin which is toxic due to the aggregation of phosphorylated desmin in failing 
heart. 
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Table. Modulation of OGA inhibition by thiamet G in isolated perfused heart 
 
Parameters Sham-rats 
Ctrl (n=6)            TG 
(n=6) 
HF-rats 
Ctrl (n=6)            TG 
(n=7) 
LV developed pressure 
(mmHg) 
134 ± 2 135 ± 10 84 ± 11 99 ± 10* 
Coronary flow (mL/min) 29 ± 2 21 ± 6* 28 ± 4 34 ± 5 
Heart rate (bpm) 248 ± 1 243 ± 12 316 ± 24 283 ± 14 
Cardiac output (mmHg) 48 ± 5 47 ± 9 30 ± 2 33 ± 2* 
Ctrl: perfusion without pharmacological agents; TG: thiamet G (200 µM); bpm: beats per 
minute 
* P<0.05 vs control in each group 
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FIGURES LEGENDS 
Figure 1: Post-translational modifications of desmin of LV from HF-rats. Quantification of 
Ser-phosphorylated desmin (A), total desmin levels (B), and O-GlcNAcylated desmin levels (C) 
in LV (50 µg) of sham-(n=11) (white box) and HF- (n=11) (black box) rats at 2 months after MI. 
The positions of molecular weight are indicated as kilodalton (kDa) on the left. An internal 
standard was loaded in each gel for the standardization and quantification. Graphs show mean ± 
SEM values expressed in arbitrary units (A.U.). * P <0.05; ** P <0.01. 
Figure 2: Impact of OGA inhibition by thiamet G in primary cultures of NCM. A: 
Description of the protocol designed for Thiamet G (TG) treatment of primary culture of neonate 
cardiomyocytes (NCM). B: Representative western blots (left panel) and quantification (right 
panel) of O-GlcNAcylated proteins levels in control (Ctrl) and NCM treated with 100 nM of 
thiamet G (TG) during 24h (n=12). C: Western blots (upper panel) and quantification (lower 
panel) of total desmin levels in the same samples. D: Phosphorylation profiles of desmin were 
analyzed in the same samples by Phos-tag™ gel. E: Representative immunoprecipation (IP) with 
desmin antibody before western blot with RL2 antibody (left panel) and quantification (right 
panel) of O-GlcNAcylated desmin levels in the same samples. Inp: input, IP: immunoprecipitated 
proteins, S: IP supernatant, Des: desmin, IgG: Immunoglobulin. The arrow indicates the O-
GlcNAcylated desmin. Data are expressed as means of an arbitrary unit (A.U.) ± SEM. The 
positions of molecular weight are indicated as kilodalton (kDa) on the left. **P<0.01. 
Figure 3: Effect of OGT silencing in primary cultures of NCM. A: Description of the protocol 
designed for OGT silencing of primary cultures of NCM. B: Western blots (left panel) and 
quantification of O-GlcNAcylated proteins levels (upper and right panel) and OGT (lower and 
right panel) in primary cultures of NCM transfected with non-targeting (NT) siRNA control and 
OGT1 and OGT2 siRNA (n =12). C: Western blots (upper panel) and quantification (lower 
panel) of total desmin levels in the same samples. D: Phosphorylation profiles of desmin was 
analysed in the same samples by Phos-tag™ gel. E: Representative immunoprecipation (IP) with 
desmin antibody before western blot with RL2 antibody (left panel) and quantification (right 
panel) of O-GlcNAcylated desmin levels in the same samples. Inp: input, IP: immunoprecipitated 
proteins, S: IP supernatant, B: beads alone, S*: IP supernatant of beads. The arrow indicates the 
O-GlcNAcylated desmin. Graphs show mean ± SEM values expressed in arbitrary units (A.U.). 
The positions of molecular weight are indicated as kilodalton (kDa) on the left. *P<0.005; 
**P<0.01 
Figure 4: Effect of OGA inhibition by thiamet G in isolated perfused heart. A: Description 
of the protocol designed for thiamet G (TG) perfusion in sham- (n=6) and HF- (n=7) rats 6 weeks 
post-MI. B: Western blot (left panel) and quantification (right panel) of O-GlcNAcylated proteins 
levels measured in proteins extracted from LVs of isolated perfused sham- and HF-rat hearts 
treated or not with 100 µM thiamet G for 2 hr (n =7 in each group). C: Western blots (upper 
panel) and quantification (lower panel) of total desmin levels in the same samples. D: 
Phosphorylation profiles of desmin were analyzed in the same samples by Phos-tag™ gel.  
Graphs show mean ± SEM values expressed in arbitrary units (A.U.). The positions of molecular 
weight are indicated as kilodalton (kDa) on the left. * P <0.05; ** <0.01 
Figure 5: Analysis of O-GlcNAcylated LV proteins by Western blot and WGA-SDS-PAGE 
gel electrophoresis. A: Red ponceau staining (left panel) and western blot (right panel) of O-
GlcNAcylated proteins (50 µg) extracted from sham- and HF-rats treated or not with thiamet G. 
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The positions of molecular weight are indicated as kilodalton (kDa) on the left. B: Red ponceau 
staining (left panel) and WGA-SDS-PAGE of O-GlcNAcylated proteins levels (middle panel) of 
O-GlcNAcylated desmin levels (right panel) from the same samples. The arrow in desmin WGA 
gels indicates the non- O-GlcNAcylated form. 
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